NCT03638076View on ClinicalTrials.gov

The Safety, Antiviral Activity, and Pharmacokinetics of Morphothiadine Mesilate Capsules

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 26, 2017

Primary Completion Date

November 22, 2018

Study Completion Date

November 29, 2018

Conditions
Chronic Hepatitis B
Interventions
DRUG

GLS4

Subject in group A will receive Mesilate Capsule 120mg twice daily. Subject in group B will receive Mesilate Capsule 120mg three times daily.

DRUG

RTV

Subject in group A will receive Ritonavir tablet 100mg twice daily.Subject in group B will receive Ritonavir tablet 100mg three times daily.

Trial Locations (1)

130021

The First Hospital of Jilin University, Changchun

All Listed Sponsors
lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY

NCT03638076 - The Safety, Antiviral Activity, and Pharmacokinetics of Morphothiadine Mesilate Capsules | Biotech Hunter | Biotech Hunter